Rusfertide (hepcidin mimetic for PV)

Current understanding

To be populated as evidence accumulates.

2026-10-05 — A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera: cross-connection with ag-236: Both AG-236 and rusfertide are investigational phlebotomy-sparing agents in PV, offering a comparator class for erythrocytosis control endpoints. (novelty: 3)
2026-08-31 — FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo): FDA approval granted for rusfertide (Mimrylo) in adults with polycythemia vera not adequately controlled by existing therapies — first hepcidin-mimetic drug approved for PV (regulatory announcement). (novelty: 4)
2026-06-15 — A Study of Rusfertide in Japanese Adults With Polycythemia Vera: Open-label single-arm trial evaluating rusfertide for hematocrit control and phlebotomy reduction in Japanese adults with PV over up to 244 weeks, extending prior Phase 2 evidence to a Japanese population (geographic/ethnic generalizability). (novelty: 3)